ISSCR News
Advocating for Regulations that Facilitate Safe and Efficacious Therapies
Last December, nearly 40 professionals with the U.S. Food and Drug Administration (FDA) gathered with ISSCR leaders to discuss advances in the development of stem cell therapies. The attendance of FDA leaders – Peter Marks, Director, Center for Biologics Evaluation and Research (CBER), Celia Witten, Deputy Director, CBER, and Wilson Bryan, Director, Office of Tissues and Advanced Therapies (OTAT) – signals how important it is for the agency to discuss scientifically informed recommendations from the ISSCR as new stem cell-based therapies advance.
The ISSCR Comments on the MHRA Consultation on Point of Care Manufacturing
The ISSCR submitted comments to the UK's MHRA on the Consultation on Point of Care Manufacturing that state, among other key points…
The ISSCR submitted comments on the CY 2022 Medicare OPPS and APC Proposed Rule
The ISSCR submitted comments on the CY 2022 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule (CMS-1753-P).
The ISSCR Comments on the Australian Mitochondrial Donation Bill
The ISSCR provided formal support of the Mitochondrial Donation Law Reform (Maeve's Law) Bill 2021 in a letter to Chair Wendy Askew and Deputy Chair Rachel Siewert of the Senate Community Affairs Legislation Committee in Australia.
Coalition Statement in Support of Research Using Human Fetal Tissue
Our organizations represent scientific, medical, and patient communities dedicated to advancing medical knowledge and improving human health. We support the continued use of human fetal tissue (HFT) in research because it is an indispensable biomedical research tool crucial for life-saving biomedical research.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .